Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
GH Research PLC(GHRS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GHRS
11/06/2026: GHRS (3-star) is currently NOT-A-BUY. Pass it for now.
GH Research PLC is a clinical-stage biotechnology company focused on developing proprietary 5-MeO-DMT therapies for treatment-resistant depression and other neurological conditions. The company’s core strength lies in its specialized research program and promising preliminary clinical data regarding its lead candidate, GH001. Its primary growth opportunity centers on successfully navigating the clinical trial and regulatory process to reach commercialization in a massive mental health market. Investors must weigh this potential against high execution, regulatory, and competitive risks, as the firm is currently pre-revenue and depends on external funding. GH Research is suited for speculative growth investors who closely monitor clinical data and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | GH Research offers high-growth potential if clinical trials succeed, though it remains a speculative, high-risk bet. |
| Momentum investor | Weak fit | This stock is generally driven by news cycles rather than sustained price trends; it is a weak fit unless a major positive catalyst occurs. |
| Value investor | Weak fit | As a pre-revenue company with significant cash burn, it lacks the earnings or assets required for a value-based investment thesis. |
| Dividend investor | Weak fit | The company does not pay dividends and is not suitable for income-focused portfolios. |
| Low-risk investor | Weak fit | High clinical and regulatory uncertainty makes this unsuitable for low-risk, conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience extreme swings based on trial data and regulatory news. |
| Valuation risk | High | Valuation is highly subjective as it is based entirely on the probability of future clinical and commercial success. |
| Competition risk (psychedelic therapeutics) | Medium / high | Multiple companies are racing to bring similar or superior neurological treatments to market. |
| Business quality | Medium | The company's viability is entirely tied to the success of its intellectual property and clinical development program. |
| Dividend income | Low / none | There is no potential for dividend income in the foreseeable future. |
| Execution risk | High | Failure to meet clinical endpoints or secure regulatory approval would severely threaten the company's future. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 108.18% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.28B USD | Price to earnings Ratio - | 1Y Target Price 42.89 |
Price to earnings Ratio - | 1Y Target Price 42.89 | ||
Volume (30-day avg) 371.7K shares | Beta 1.32 | 52 Weeks Range 12.04 - 31.44 | Updated Date 11/08/2026 |
52 Weeks Range 12.04 - 31.44 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development (Pre-Revenue) | Clinical stage research and development of 5-MeO-DMT based therapies. | The company is currently spending money to invent new drugs and does not sell any products yet. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 911.71M | Price to Sales(TTM) - |
Enterprise Value 911.71M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.97 | Shares Outstanding 68.64M | Shares Floating 32.37M |
Shares Outstanding 68.64M | Shares Floating 32.37M | ||
Percent Insiders 24.46 | Percent Institutions 71.78 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.